These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 26339766)
1. The mast cell as a pluripotent HDL-modifying effector in atherogenesis: from in vitro to in vivo significance. Lee-Rueckert M; Kovanen PT Curr Opin Lipidol; 2015 Oct; 26(5):362-8. PubMed ID: 26339766 [TBL] [Abstract][Full Text] [Related]
2. Mast cell proteases: physiological tools to study functional significance of high density lipoproteins in the initiation of reverse cholesterol transport. Lee-Rueckert M; Kovanen PT Atherosclerosis; 2006 Nov; 189(1):8-18. PubMed ID: 16530202 [TBL] [Abstract][Full Text] [Related]
3. Mast cell-dependent proteolytic modification of HDL particles during anaphylactic shock in the mouse reduces their ability to induce cholesterol efflux from macrophage foam cells ex vivo. Judström I; Jukkola H; Metso J; Jauhiainen M; Kovanen PT; Lee-Rueckert M Atherosclerosis; 2010 Jan; 208(1):148-54. PubMed ID: 19679305 [TBL] [Abstract][Full Text] [Related]
4. The mast cell--a potential link between inflammation and cellular cholesterol deposition in atherogenesis. Kovanen PT Eur Heart J; 1993 Dec; 14 Suppl K():105-17. PubMed ID: 8131778 [TBL] [Abstract][Full Text] [Related]
5. Extracellular modifications of HDL in vivo and the emerging concept of proteolytic inactivation of preβ-HDL. Lee-Rueckert M; Kovanen PT Curr Opin Lipidol; 2011 Oct; 22(5):394-402. PubMed ID: 21881503 [TBL] [Abstract][Full Text] [Related]
6. Depletion of pre beta 1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma. Lee M; von Eckardstein A; Lindstedt L; Assmann G; Kovanen PT Arterioscler Thromb Vasc Biol; 1999 Apr; 19(4):1066-74. PubMed ID: 10195937 [TBL] [Abstract][Full Text] [Related]
7. Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid. Lindstedt L; Lee M; Castro GR; Fruchart JC; Kovanen PT J Clin Invest; 1996 May; 97(10):2174-82. PubMed ID: 8636396 [TBL] [Abstract][Full Text] [Related]
8. Enhanced vascular permeability facilitates entry of plasma HDL and promotes macrophage-reverse cholesterol transport from skin in mice. Kareinen I; Cedó L; Silvennoinen R; Laurila PP; Jauhiainen M; Julve J; Blanco-Vaca F; Escola-Gil JC; Kovanen PT; Lee-Rueckert M J Lipid Res; 2015 Feb; 56(2):241-53. PubMed ID: 25473102 [TBL] [Abstract][Full Text] [Related]
9. Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol. Lee M; Sommerhoff CP; von Eckardstein A; Zettl F; Fritz H; Kovanen PT Arterioscler Thromb Vasc Biol; 2002 Dec; 22(12):2086-91. PubMed ID: 12482839 [TBL] [Abstract][Full Text] [Related]
10. Mast cell-mediated inhibition of reverse cholesterol transport. Lee M; Lindstedt LK; Kovanen PT Arterioscler Thromb; 1992 Nov; 12(11):1329-35. PubMed ID: 1420092 [TBL] [Abstract][Full Text] [Related]
11. Plasmin and kallikrein reduce HDL-induced cholesterol efflux from foam cells. Lindstedt L; Kovanen PT Biochem Biophys Res Commun; 2000 Nov; 277(3):552-7. PubMed ID: 11061992 [TBL] [Abstract][Full Text] [Related]